Lineage Cell Therapeutics
LCTX
LCTX
110 hedge funds and large institutions have $149M invested in Lineage Cell Therapeutics in 2025 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 23 increasing their positions, 33 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
15% less funds holding
Funds holding: 129 → 110 (-19)
30% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 33
50% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 34
Holders
110
Holding in Top 10
3
Calls
$650K
Puts
$85K
Top Buyers
| 1 | +$886K | |
| 2 | +$747K | |
| 3 | +$690K | |
| 4 |
QC
Quadrature Capital
London,
United Kingdom
|
+$304K |
| 5 |
Morgan Stanley
New York
|
+$286K |
Top Sellers
| 1 | -$6.16M | |
| 2 | -$2.3M | |
| 3 | -$672K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$612K |
| 5 |
Squarepoint
New York
|
-$464K |
